<DOC>
	<DOCNO>NCT00431431</DOCNO>
	<brief_summary>Both tibolone raloxifene demonstrate prevent postmenopausal bone loss . During treatment tibolone bone mineral density ( BMD ) spine show increase 1.8 5.8 % baseline two year , depend population study . Since treatment aim prevention ideally use long-term , compliance treatment crucial . Efficacy compliance two treatment measure evaluate .</brief_summary>
	<brief_title>Comparison Tibolone Raloxifene Bone Mineral Density Osteopenic Postmenopausal Women ( P06090 )</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<criteria>Only subject give voluntary write informed consent , willing able make reasonable effort observe clinical trial requirement enrol . Subjects osteopenic otherwise healthy postmenopausal woman , 60 79 year age ( inclusive ) entry . Screening BMD lumbar vertebra ( L1L4 ) must 2.5 SD 1.0 SD Tscore . Subjects Body Mass Index ( BMI ) &gt; 19 &lt; 30 kg/m2 . Spinal X ray symptomatic vertebral fracture ( 20 % reduction expect vertebral height ) . History bilateral hip replacement . Subjects ambulatory . History presence malignancy , except nonmelanoma skin cancer . TVUS double wall thickness &gt; 4 mm , undiagnosed abnormality visualize TVUS . Abnormal cervical Pap smear result Undiagnosed abnormal ( investigator 's opinion ) vaginal bleeding past year prior screen . Mammography physical examination find suspicious malignancy . Uncontrolled hypertension Bone disease osteoporosis Paget 's disease , osteomalacia bone metastasis . Drinking 4 glass alcohol contain drink per day . Smoking 20 cigarette day . Current recent prolong use hepatic microsomal enzymeinducing anticonvulsant medication drug know interfere otherwise alter pharmacokinetics steroid . Treatment anabolic steroid , calcitonin raloxifene within last 6 month . Treatment alendronate risedronate 6 month . If treatment duration le 6 month washout period 12 month necessary . Treatment etidronate 1 year washout period 6 month necessary . If treatment period 1 year wash period 12 month necessary . Treatment oral estrogen and/or progestin therapy ( include contraceptive ) transdermal therapy local estrogen application within 6 month prior screening/baseline BMD measurement ( i.e . wash period 6 month must complete screen / baseline BMD assessment make ) . A 20week washout injection MPAcontaining contraceptive ( e.g . DepoProveraÂ® ) require . Ever use estrogen and/or progestin contain implant . The use cholesterollowering medicine cholestyramine colestipol . Subjects change thyroid medication within last 6 week prior screen . Subjects fluoride treatment 2 week ( &gt; 2 mg/day fluorideion ) time ( NaF tablets caries prevention allow ) . Subjects undergone systemic glucocorticoid treatment ( &gt; 5 mg prednisone equivalent/day ) one month within past 6 month ( prior BMD screen assessment ) . Subjects receive require medication treatment osteoporosis except Calcium / Vit D. The use coumarin product . Type I diabetes mellitus . Presence history thromboembolic disorder . Serious decompensated renal liver disease . Abnormal laboratory value Any condition disease could result altered absorption , excessive accumulation , impaired metabolism , altered excretion investigational product .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>